Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vioxx, Drug Safety Issues Top Health Committee Agenda – If Gregg Stays

Executive Summary

The Senate Health Committee plans to look into FDA's handling of Vioxx, antidepressant safety and flu vaccine, committee counsel Steve Irizarry said at the Healthcare Distribution Management Association annual meeting in Palm Desert, Calif. Nov. 4

You may also be interested in...



Senate Cmte. Shuffle Brings Importation Advocate Specter To Judiciary

Two key Senate committees for the pharmaceutical industry will have new chairmen in the 109 Congress, and both of them favor importation

Senate Cmte. Shuffle Brings Importation Advocate Specter To Judiciary

Two key Senate committees for the pharmaceutical industry will have new chairmen in the 109 Congress, and both of them favor importation

Sen. Gregg moves to Budget Cmte.

Senate Health Committee Chairman Judd Gregg (R-N.H.) will retain responsibility over Medicare on a macro level following his move to the chairmanship of the Budget Committee. At his announcement of his plan to seek the Budget Committee's chairmanship Nov. 10, Gregg says he expects Sen. Michael Enzi (R-Wyo.), the most senior member of the Health Committee, to become chair. Health Committee Counsel Steve Irizarry says priorities on the committee's 2005 agenda include drug safety and flu vaccine (1"The Pink Sheet" Nov. 8, 2004, p. 4)...

Related Content

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel